Evidence date · 2023-01-31 · Research note 3 of 3
1 2 3
See current Track status →
Since the previous research note · Partly supported
Track continuity
Since the previous research note: How light-activated cancer treatment works and what limits its wider use
Previous expectation: Bringing targeted light through a scope or into a treatment field might extend local care to tumors external light cannot reach, if delivery proves safe and beneficial.
What this study adds: The 2023 review describes internal light-delivery approaches and cites reduced tumor growth with a catheter in mouse xenografts, while broadening the track’s focus to targeting and immune effects. It does not establish better outcomes for patients with deeper tumors or test the proposed surgical-field use.
What changed in this study
At an illuminated site, near-infrared photoimmunotherapy can damage cells bound by a targeting molecule linked to a light-sensitive dye. Yet the cell damage may also release signals that activate immune defenses, raising the possibility of effects beyond the treated area. A 2023 review of near-infrared photoimmunotherapy (NIR-PIT) brings these two scales together: a local treatment mechanism and a possible wider immune response. The second remains a possibility, not an established benefit for patients with distant metastases.
A targeted dye turns light into local cell damage
NIR-PIT depends on two inputs reaching the same place. First, a targeting molecule—often an antibody or a smaller antibody fragment—must bind a marker on the surface of a cancer cell or another chosen cell. That molecule is linked to IRdye700, a light-sensitive dye. Then near-infrared light must reach the bound dye.
When illuminated, IRdye700 undergoes a chemical change that makes the bound material less soluble in water. It can then clump on the cell membrane and disrupt it. The targeted cell swells and its membrane breaks, releasing its contents. This differs from treatments that depend on producing reactive oxygen molecules: the review describes membrane damage as NIR-PIT’s key local action.
The selectivity comes from combining target binding with local illumination. A cell without the relevant target is less likely to receive the dye, while a dye-bound cell outside the illuminated area does not receive the same light trigger. Selectivity is therefore a design aim, not a guarantee that every cancer cell in a tumor will be reached.
Damaged cells may recruit immune defenses
The local destruction can begin a second process. Dying tumor cells release tumor antigens—molecules the immune system can recognize—and signals of cell damage. Those signals can help one group of immune cells, called dendritic cells, activate another group, CD8 T cells, which may then multiply and attack remaining cancer cells.
If activated immune cells travel through the body, they could also encounter cancer deposits beyond the illuminated site. The review discusses this as a potential systemic response, while also noting that immune suppression in the tumor environment can weaken it. Regulatory cells, including tumor-infiltrating T cells that restrain immune activity, can dampen the response. NIR-PIT aimed at such suppressive cells is one proposed way to remove some of that brake locally, alongside treatment aimed at cancer cells.
This is a biological route by which treatment of one site might matter elsewhere. It does not mean that light itself reaches distant deposits, or that a local response reliably controls them. The review synthesizes mechanisms and studies; it provides no pooled estimate of patient benefit from distant immune effects.
The target molecule determines which cells can be reached
NIR-PIT is a family of treatments built around different targeting molecules, not one dye that recognizes every cancer. The review describes antibodies, antibody fragments, and smaller antibody-like molecules linked to IRdye700. The review surveys targets on cancer cells, such as EGFR, and targets on immune-suppressing cells in tumors, such as CD25. A target is useful when it is sufficiently present on the intended cells and can be recognized by the attached molecule.
EGFR provides a prominent example. The review reports that cetuximab linked to IRdye700 was conditionally approved for clinical use in Japan in 2020. That milestone concerns one agent and its reported status; it does not establish efficacy or availability for every target or cancer discussed in the review.
Building a consistent agent is part of the challenge. The review notes that dye attachment can produce impurities, mixtures that vary between batches, or aggregates. The dye can also attach near a molecule’s recognition site and interfere with its ability to bind. These problems matter because the treatment relies on the targeting molecule bringing enough active dye to the intended cell surface.
Smaller antibody fragments may enter tumor tissue more readily and clear from tissue faster than full-sized antibodies, according to the review. But fragments lack the antibody region involved in some immune responses. The choice of targeting molecule therefore affects more than size: it shapes where the dye goes and how the immune system may interact with the treatment.
Internal light delivery changes which sites are reachable
External near-infrared illumination is suited to accessible tissue, such as tumors in the mouth or skin. The review gives an approximate penetration depth of about 2 cm from the tissue surface. That reach makes the position and depth of a tumor important; a target can be well chosen and still be difficult to illuminate from outside the body.
Endoscopic fiber-optic diffusers offer a way to carry light into deeper sites. The review describes their use under endoscopic guidance for tumors in locations such as the abdomen or chest. It also discusses a catheter fitted with LEDs, a temperature sensor, and features intended to support insertion and illumination. In mice bearing implanted bile-duct tumors, the catheter approach was associated with significantly reduced tumor growth. This is an animal result, not evidence that deep human tumors can be treated safely or effectively with the device.
A separate endovascular approach described in the review directs light from within blood vessels toward nearby tissue. These approaches change the physical route by which light can reach a site. They do not by themselves resolve how evenly the targeting molecule reaches cancer cells within that site.
Dye distribution can remain uneven inside a tumor
Light access and dye distribution are separate constraints. The review describes recurrence in treated mice associated with uneven distribution of antibody-dye conjugates within tumors. Because antibodies are relatively large, their concentration can vary across tumor tissue. Areas with less bound conjugate may receive less of the light-triggered damage even when the treatment field is illuminated.
The review discusses repeated light exposure guided by the dye’s fluorescence as one response to uneven distribution. It also describes adding a second, lower-affinity antibody to help binding extend farther into a tumor. These strategies address different parts of the delivery problem, and the cited recurrence observations come from mice. The review also cautions that repeated treatment’s long-term side effects were not investigated in the evidence it discusses; the safety of repeated courses is therefore not settled by those observations.
Imaging can show treatment activity, not lasting benefit
Imaging can help teams see where the dye has accumulated and whether illumination has changed its signal. IRdye700 fluorescence can be detected in tumor tissue before exposure, then diminish after illumination as the dye-linked proteins precipitate. A customized camera system described in the review can detect the fluorescence during procedures. Such changes help monitor the agent and the immediate treatment process; they are not, on their own, proof of durable tumor control or improved outcomes for patients.
The review also describes PET scans for changes in a tumor’s glucose use and MRI scans for early tissue effects. These measures add information about response soon after treatment; they cannot establish whether the effect lasts.
What light-triggered immunity could change
If local tumor damage reliably activated immune cells that could overcome suppression and reach distant cancer, NIR-PIT might extend the value of treating an accessible tumor to disease elsewhere in the body. Pairing cancer-cell targeting with local removal of immune-suppressing cells is one route the review discusses toward that possibility. For patients, the potential consequence would be control beyond the illuminated site, without requiring light to reach every deposit.
That consequence depends on several links holding together: enough targeted dye must bind the right cells, light must reach the treatment site, cell damage must activate useful immunity, and that response must persist despite tumor defenses. The review describes progress in targeting, internal light delivery, and monitoring, but it does not establish durable control of distant metastases in patients. The wider effect remains a proposed benefit whose clinical reach is still unresolved.
Key Sources
- Primary source: Near Infrared Photoimmunotherapy: A Review of Recent Progress and Their Target Molecules for Cancer Therapy.
DOI or Journal Page · Review or Meta-Analysis · 2023-01-31